Emery Manirambona

Dr. Emery Manirambona

University of Rwanda, Kigali, Rwanda
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Public Health Reviews
Verified
Journal Article
Open access
SMSulaiman Muhammad Musa
Sulaiman Muhammad Musa
UHUsman Abubakar Haruna
Usman Abubakar Haruna
EMEmery Manirambona
Emery Manirambona
GEGilbert Eshun
Gilbert Eshun
DADalhatu Muhammad Ahmad
Dalhatu Muhammad Ahmad
DIDon Eliseo Lucero-Prisno Iii
Don Eliseo Lucero-Prisno Iii
Background: Among the numerous challenges that Africa faces in improving its healthcare systems, the paucity of health data stands out as paramount. This study aims to examine the challenges related to the paucity of health data in Africa and its impact on the implementation of digital health and evidence-based practice. The findings of the study reveal that health data availability in Africa is both limited and frequently of poor quality. Several factors contribute to this concerning situation, encompassing inadequate infrastructure, a shortage of resources, and cultural barriers. Furthermore, the available data, despite its limitations, is often underutilized due to a lack of capacity and expertise in data analysis and interpretation.Policy Options and Recommendations: To improve healthcare delivery in Africa, we recommend implementing novel strategies for data collection. It’s important to recognize that effective information technology service is crucial for enhancing healthcare delivery, and a holistic approach is necessary to achieve this.Conclusion: This brief presents information to help policymakers develop long-term solutions to Africa’s health data poverty. Taking action based on this evidence can assist in addressing the problem.

28 June 2024 in Discover Public Health
Verified
Journal Article
Open access
PDF file
EMEmery Manirambona
Emery Manirambona
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
NONoah Olabode Olaleke
Noah Olabode Olaleke
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
SARS-CoV-2, the cause of the COVID-19 pandemic, has introduced a challenging era characterized by the persistent emergence of subvariants. Even after the World Health Organization announced the end of the pandemic, the virus continues to evolve, posing significant challenges to public health responses. This comprehensive review examines the multifaceted impacts of these subvariants, emphasizing their significance across diverse dimensions. SARS-CoV-2 has genetic variability, especially at the spike protein region, which has given rise to Variants of Concern, including Beta, Delta, Gamma, Alpha, and the highly mutable Omicron, which differently exhibit varying levels of immune evasion, disease severity, and transmissibility. Subvariants within the Omicron lineage, including BA.1, BA.2, BA.3, and others, further complicate the landscape with distinct genetic signatures and varying infectivity levels. The impacts extend to diagnostic techniques, treatment strategies, and vaccine effectiveness, underscoring the need for a comprehensive public health response emphasizing preventive measures, genomic surveillance, and vaccination campaigns. Sustaining these interventions is critical, necessitating long-term strategies considering socio-political factors, community involvement, continuous adaptation of healthcare approaches, robust monitoring, and sustainable public health interventions to effectively combat the virus's ever-changing landscape.

2 April 2025 in Tropical Medicine and Health
Verified
Journal Article
Open access
PDF file
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
MAMohamed Mustaf Ahmed
Mohamed Mustaf Ahmed
JOJerico Bautista Ogaya
Jerico Bautista Ogaya
BABlessing Olawunmi Amisu
Blessing Olawunmi Amisu
BUBonaventure Ukoaka
Bonaventure Ukoaka
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Background: Antimicrobial resistance (AMR) poses a global health threat, particularly in low- and middle-income countries (LMICs). Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas system technology offers a promising tool to combat AMR by targeting and disabling resistance genes in WHO bacterial priority pathogens. Thus, we systematically reviewed the potential of CRISPR–Cas technology to address AMR. Methods: This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted using the Scopus and PubMed databases, focusing on publications from 2014 to June 2024. Keywords included “CRISPR/Cas,” “antimicrobial resistance,” and “pathogen.” The eligibility criteria required original studies involving CRISPR/Cas systems that targeted AMR. Data were extracted from eligible studies, qualitatively synthesized, and assessed for bias using the Joanna Briggs Institute (JBI)-standardized tool. Results: Data from 48 eligible studies revealed diverse CRISPR–Cas systems, including CRISPR–Cas9, CRISPR–Cas12a, and CRISPR–Cas3, targeting various AMR genes, such as blaOXA-232, blaNDM, blaCTX-M, ermB, vanA, mecA, fosA3, blaKPC, and mcr-1, which are responsible for carbapenem, cephalosporin, methicillin, macrolide, vancomycin, colistin, and fosfomycin resistance. Some studies have explored the role of CRISPR in virulence gene suppression, including enterotoxin genes, tsst1, and iutA in Staphylococcus aureus and Klebsiella pneumoniae. Delivery mechanisms include bacteriophages, nanoparticles, electro-transformation, and conjugative plasmids, which demonstrate high efficiency in vitro and in vivo. CRISPR-based diagnostic applications have demonstrated high sensitivity and specificity, with detection limits as low as 2.7 × 102 CFU/mL, significantly outperforming conventional methods. Experimental studies have reported significant reductions in resistant bacterial populations and complete suppression of the targeted strains. Engineered phagemid particles and plasmid-curing systems have been shown to eliminate IncF plasmids, cured plasmids carrying vanA, mcr-1, and blaNDM with 94% efficiency, and restore antibiotic susceptibility. Gene re-sensitization strategies have been used to restore fosfomycin susceptibility in E. coli and eliminate blaKPC-2-mediated carbapenem resistance in MDR bacteria. Whole-genome sequencing and bioinformatics tools have provided deeper insights into CRISPR-mediated defense mechanisms. Optimization strategies have significantly enhanced gene-editing efficiencies, offering a promising approach for tackling AMR in high-priority WHO pathogens. Conclusions: CRISPR–Cas technology has the potential to address AMR across priority WHO pathogens. While promising, challenges in optimizing in vivo delivery, mitigating potential resistance, and navigating ethical-regulatory barriers must be addressed to facilitate clinical translation.

1 November 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
POPius Omoruyi Omosigho
Pius Omoruyi Omosigho
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
MMMohamed Babiker Musa
Mohamed Babiker Musa
YAYoussry Mohamed Elsawy Ibrahim Aboelhassan
Youssry Mohamed Elsawy Ibrahim Aboelhassan
OOOlaleke Noah Olabode
Olaleke Noah Olabode
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Stigma poses a significant barrier to accessing care, managing, and preventing infectious diseases in Africa. The authors conducted an extensive search across Scopus, PubMed, ScienceDirect, and Google Scholar to identify relevant English-language articles, with no constraints on publication dates, using the keywords “Stigma,” and “Infectious Disease,” in conjunction with “Africa.” This article explores the multifaceted nature of stigma associated with infectious diseases, highlighting its impact on healthcare access and public health outcomes. It delves into the current situation of infectious disease-related stigma in Africa, emphasizing the various diseases and contexts affected. The article identifies drivers of stigma, including negative attitudes, misinformation, and institutional practices, and discusses their role in perpetuating discrimination. Importantly, it provides recommendations for addressing infectious disease stigma in Africa through comprehensive strategies encompassing health education, contact-based interventions, professionalized counselling and peer support services, and community engagement. The article calls for collaboration among governments, healthcare organizations, NGOs, and community leaders to implement holistic strategies that prioritize inclusivity and stigma reduction. Ultimately, it underscores the urgent need to combat stigma to improve healthcare access and outcomes for individuals affected by infectious diseases in Africa.

1 October 2024 in Adolescent Health, Medicine and Therapeutics
Verified
Journal Article
Open access
PDF file
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
GOGbolahan Olatunji
Gbolahan Olatunji
NONoah Olabode Olaleke
Noah Olabode Olaleke
MMMba Oluebube Mercy
Mba Oluebube Mercy
AIAyodele Ilesanmi
Ayodele Ilesanmi
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
African immunization programs are crucial in reducing the prevalence of infectious diseases and improving public health outcomes. This review provides an overview of the current status of immunization efforts in Africa, highlights key challenges, and offers recommendations to help the continent achieve the 2030 Global Immunization Goals. While progress has been made, significant challenges remain. For instance, the WHO African Region reports full immunization coverage at 56.5%, partial coverage at 35.1%, and zero immunization coverage at 8.4%. Between 2019 and 2021, approximately 67 million children in Africa did not receive routine vaccinations, with West and Central Africa particularly affected. DTP1 coverage remained stable at 80%, but DTP3 coverage saw a slight drop to 72% between 2021 and 2022. As of 2022, MCV1 coverage reached 69%, reflecting ongoing efforts against measles. Key barriers to vaccination include limited parental education, religious beliefs, inadequate healthcare systems, and vaccine hesitancy. Addressing these barriers requires community-driven approaches like door-to-door campaigns and mobile clinics. To reach the 2030 immunization targets, health systems must be strengthened, vaccine supply chains optimized, and financial resources—both domestic and international—expanded. The Immunization Agenda 2030 (IA2030) emphasizes data-driven decision-making, nation-ownership, and tailored strategies to overcome obstacles and raise immunization coverage among several demographic groups. Achieving these 2030 goals in Africa requires collaborative efforts to ensure equitable access to vaccines, address sociocultural challenges, and strengthen health system infrastructure.

30 December 2024 in Public Health Challenges
Verified
Journal Article
Open access
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
DSDeborah Oluwaseun Shomuyiwa
Deborah Oluwaseun Shomuyiwa
MKM. B. N. Kouwenhoven
M. B. N. Kouwenhoven
TDThinley Dorji
Thinley Dorji
YAYusuff Adebayo Adebisi
Yusuff Adebayo Adebisi
MWMartin Cs Wong
Martin Cs Wong
As we navigate the complex landscape of global public health in 2024, this article provides a comprehensive exploration of challenges, ranging from infectious diseases, mental health, and substance use to environmental sustainability and emerging technologies. The aftermath of the COVID‐19 pandemic underscores the critical need to strengthen health systems, increase public financing, and foster effective international collaboration. The intricacies of global geopolitics, diplomacy, and public health highlight the importance of countries that do not address shared challenges through enhanced cooperative mechanisms and joint initiatives. From the imperative of global health security to the persistence of non‐communicable diseases and health disparities, this study delves into multifaceted issues, advocating for collective action, targeted interventions, and a commitment to prioritizing public health on a global scale. Focusing on addressing root causes and fostering equity, this study emphasizes the role of sustainable practices, community engagement, and intersectionality of research in building a resilient global health landscape. In this dynamic environment, 2024 calls for a unified global vision that encourages nations to collaborate more effectively to build a healthier and more resilient global community, ultimately paving the way for a future characterized by a shared commitment to public health challenges.